APOB and diabetes mellitus: When CARDIA participants who initiated lipid-lowering therapy during follow-up were removed from the analysis dataset, the mean BMI, TG level, glucose, and DM prevalence in the lowest rate of change quartile at Y20 were lower than observed in the primary analysis, suggesting that some of the decrease in apoB in that group was due to the use of lipid-lowering therapy in higher risk individuals.